Vimarsana
Biggest News Aggregation in the World

World Heart News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from World Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In World Heart Today - Breaking & Trending Today

Skeptical Science New Research for Week #22 2024 - Vimarsana News

Skeptical Science New Research for Week #22 2024

Open access notables Unveiling Unprecedented Methane Hotspots in China's Leading Coal Production Hub: A Satellite Mapping Revelation, Han et al., Geophysical Research Letters:

As many as 1.9 million people dying every year from heart disease due to outdoor air pollution: World Heart Federation - Vimarsana News

As many as 1.9 million people dying every year from heart disease due to outdoor air pollution: World Heart Federation

Latest statistics and report by the World Heart Federation on the effects of air pollution on heart health around the world

INT: Air pollution-related deaths from heart conditions, obesity, diabetes are growing—and climate change partially to blame - Vimarsana News

INT: Air pollution-related deaths from heart conditions, obesity, diabetes are growing—and climate change partially to blame

InlandNewsToday is the one-stop online source for same-day news and events occurring in Riverside and San Bernardino counties in Southern California featuring news, traffic information, real-time weather and things to do, all this offered in text and webcasts/podcasts.

Sir Mo Farah missing from Oxford's 2024 final Honorary Degree list - Vimarsana News

Sir Mo Farah missing from Oxford's 2024 final Honorary Degree list

British long-distance runner Sir Mo Farah was absent from the final list announced this past week, though originally shortlisted.

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting - Vimarsana News

New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant LDL-C reduction vs. clinician-determined usual care (60% vs. 7% respectively)1 A significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm […]